Use of bisphosphonates (Bis) combined with sunitinib (Su) to improve the response rate (RR), progression-free survival (PFS), and overall survival (OS) of patients (pts) with bone metastases (mets) from renal cell carcinoma (RCC)

被引：0
|
作者：
Peer, Avivit
Ish-Shalom, Maya
Hammers, Hans J.
Eisenberger, Mario A.
Sinibaldi, Victoria J.
Pili, Roberto
Maimon, Natalie
Gottfried, Maya
Hayat, Henry
Kovel, Svetlana
Sella, Avishay
Neumann, Avivit
Boursi, Ben
Berger, Raanan
Carducci, Michael Anthony
Keizman, Daniel
机构：
[1] Rambam Hlth Care Campus, Haifa, Israel
[2] Tel Aviv Univ, Sackler Sch Med, Meir Med Ctr, Genitourinary Oncol Serv,Div Oncol, Kefar Sava, Israel
[3] Johns Hopkins Univ, Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD USA
[4] Roswell Pk Canc Inst, Buffalo, NY 14263 USA
[5] Wolfson Med Ctr, Dept Oncol, Holon, Israel
[6] Asaf Harofe Med Ctr, Dept Oncol, Zerifin, Israel
[7] Assaf Harofeh Med Ctr, IL-70300 Zerifin, Israel
[8] Rambam Med Ctr, Dept Oncol, Haifa, Israel
[9] Chaim Sheba Med Ctr, Ramat Gan, Israel
[10] Chaim Sheba Med Ctr, IL-52621 Tel Hashomer, Israel
[11] Johns Hopkins Univ, Sch Med, Baltimore, MD USA
[12] Sidney Kimmel Comprehens Canc, Baltimore, MD USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2012年 / 30卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
4619
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Radiological Response and Neutrophil-to-Lymphocyte Ratio as Predictive Factors for Progression-Free and Overall Survival in Metastatic Renal Cell Carcinoma Patients Treated with Sunitinib
    Kucharz, Jakub
    Dumnicka, Paulina
    Giza, Agnieszka
    Demkow, Urszula
    Kusnierz-Cabala, Beata
    Demkow, Tomasz
    Wiechno, Pawel
    MEDICAL SCIENCE AND RESEARCH, 2019, 1153 : 31 - 45
  • [22] The association of pre-treatment neutrophil to lymphocyte ratio with response rate, progression free survival, and overall survival of patients treated with sunitinib for metastatic renal cell carcinoma
    Keizman, Daniel
    Ish-Shalom, Maya
    Huang, Peng
    Eisenberger, Mario A.
    Pili, Roberto
    Hammers, Hans
    Carducci, Michael A.
    EUROPEAN JOURNAL OF CANCER, 2012, 48 (02) : 202 - 208
  • [23] Response to second-line chemotherapy (Ctx) in advanced urothelial carcinoma: A pooled retrospective analysis of the correlation between objective response rate (ORR) and progression-free survival (PFS) and overall survival (OS)
    Jayaram, Anuradha
    Teo, MinYuen
    McDermott, Raymond S.
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (04)
  • [24] Progression-free survival (PFS) and overall survival (OS) across ethnicities for patients with metastatic renal cell carcinoma (mRCC) receiving targeted therapies (TT) as first-line (1L) treatment
    Salgia, Nicholas
    Dizman, Nazli
    Bergerot, Paulo Gustavo
    Bergerot, Cristiane Decat
    Hsu, Joann
    Pal, Sumanta K.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (06)
  • [25] ANALYSIS OF INDIVIDUAL-LEVEL ASSOCIATION OF PROGRESSION-FREE SURVIVAL (PFS) AND TIME TO TREATMENT FAILURE (TTF) WITH OVERALL SURVIVAL (OS) FOR PREVIOUSLY UNTREATED ADVANCED RENAL CELL CARCINOMA PATIENTS IN THE CHECKMATE 214 TRIAL
    Siliman, G.
    Kanters, S.
    Fazeli, M. S.
    Pourrahmat, M. M.
    Ejzykowicz, F.
    Kurt, M.
    VALUE IN HEALTH, 2021, 24 : S20 - S20
  • [26] PREDICITIVE FACTORS OF PROGRESSION FREE SURVIVAL (PFS) AND OVERALL SURVIVAL (OS) IN ADVANCED RENAL CELL CARCINOMA (A-RCC) PATIENTS TREATED WITH TYROSINE KINASE INHIBITORS (TKIs): A RETROSPECTIVE ANALYSIS OF A MONO-INSTITUTIONAL SERIES
    Massari, Francesco
    La Russa, Francesca
    Maines, Francesca
    Bria, Emilio
    Sperduti, Isabella
    Brunelli, Matteo
    Sava, Teodoro
    Molino, Annamaria
    Artibani, Walter
    Martignoni, Guido
    Tortora, Giampaolo
    ANTICANCER RESEARCH, 2012, 32 (05) : 1854 - 1854
  • [27] Predictive factors of progression free survival (PFS) and overall survival (OS) in patients treated with tirosine kinase inhibitors (TKIs) for advanced renal cell carcinoma (A-RCC): a retrospective analysis of a mono-institutional series
    Massari, F.
    Maines, F.
    Bria, E.
    Brunelli, M.
    Sperduti, I.
    La Russa, F.
    Sava, T.
    Molino, A.
    Artibani, W.
    Martignoni, G.
    Tortora, G.
    BJU INTERNATIONAL, 2012, 110 : 6 - 6
  • [28] Impact of clinical and biological markers on progression-free survival (PFS) and overall survival (OS) in patients (pts) with advanced non-small-cell cancer (NSCLC) treated by erlotinib: results of the ERMETIC cohort
    Cadranel, Jacques
    Lizard, Sarah
    Mauguen, Audrey
    Beau-Faller, Michele
    Friard, Sylvie
    Buisine, Marie-Pierre
    Pretet, Jean-luc
    Degeorges, Armelle
    Madelaine, Jeannick
    Chouaid, Christos
    Morin, Franck
    Pignon, Jean-Pierre
    JOURNAL OF THORACIC ONCOLOGY, 2009, 4 (09) : S502 - S503
  • [29] Cabozantinib versus sunitinib for previously untreated patients with advanced renal cell carcinoma (RCC) of intermediate or poor risk: Subgroup analysis of progression-free survival (PFS) and objective response rate (ORR) in the Alliance A031203 CABOSUN trial.
    George, Daniel J.
    Hessel, Colin
    Halabi, Susan
    Sanford, Ben L.
    Michaelson, M. Dror
    Hahn, Olwen Mary
    Walsh, Meghara K.
    Olencki, Thomas
    Picus, Joel
    Small, Eric Jay
    Dakhil, Shaker R.
    Feldman, Darren R.
    Mangeshkar, Milan
    Scheffold, Christian
    Morris, Michael J.
    Choueiri, Toni K.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (06)
  • [30] Correlations between disease-free survival (DFS) and overall survival (OS) in patients (pts) with renal cell carcinoma (RCC) at high risk for recurrence: Results from S-TRAC trial
    George, D. J.
    Pantuck, A. J.
    Figlin, R.
    Escudier, B.
    Halabi, S.
    Casey, M.
    Lin, X.
    Serfass, L.
    Frean, M. J. Lechuga
    Ravaud, A.
    ANNALS OF ONCOLOGY, 2018, 29 : 312 - 312
12345